|1.||Meini, S: 2 articles (04/2002 - 03/2001)|
|2.||Lecci, A: 2 articles (04/2002 - 03/2001)|
|3.||Giuliani, S: 2 articles (04/2002 - 03/2001)|
|4.||Maggi, C A: 2 articles (04/2002 - 03/2001)|
|5.||Tramontana, M: 2 articles (04/2002 - 03/2001)|
|6.||Quartara, L: 2 articles (04/2002 - 03/2001)|
|7.||Regoli, D: 1 article (04/2002)|
|8.||Carini, F: 1 article (04/2002)|
|9.||Camarda, V: 1 article (04/2002)|
|10.||Fabbri, G: 1 article (04/2002)|
|1.||Hypotension (Low Blood Pressure)
04/01/2002 - "It is concluded that the decreased in vivo activities of cyclic analogues of MEN11270 on BK-induced BC and hypotension following either their intratracheal or their intravenous routes of administration might be due in large part to metabolic degradation."
04/01/2002 - "In this study, we describe the in vitro and in vivo activities of a series of cyclic peptide analogues of the selective kinin B2 receptor antagonist MEN11270 on Chinese hamster ovary cells expressing the human B2 receptor (hB2R), the human isolated umbilical vein (hUV), the isolated guinea pig ileum (gpI), and bradykinin (BK) induced bronchoconstriction (BC) and hypotension in anaesthetized guinea pigs. "
03/01/2001 - "The antibronchoconstrictor effect of MEN 11270 was more prolonged than that of Icatibant and FR 173657, whereas no differences were found between the peptide antagonists in inhibiting hypotension. "
03/01/2001 - "administration MEN 11270 and Icatibant (10-100 nmol/kg) dose dependently inhibited both bronchoconstriction and hypotension, whereas FR 173657 (10-100 nmol/kg) reduced bronchoconstriction without affecting hypotension. "
03/01/2001 - "The i.v. administration of MEN 11270, Icatibant, or FR 173657 induced a dose-dependent (10-100 nmol/kg) inhibition of both hypotension and bronchoconstriction induced by bradykinin (10 nmol/kg i.v.). "
|2.||Peptide Receptors (Peptide Receptor)
|5.||2,5-dichloro-4-bromophenol (B 2)